U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07141810) titled 'Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease' on Feb. 28.
Brief Summary: Early antifibrotic therapy for f-ILD
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Fibrotic Interstitial Lung Disease
Intervention:
DRUG: Antifibrotic drugs (nidanib or pirfenidone)
One group received primary therapy, and another group received an antifibrotic drug (nidanib or pirfenidone) in addition to primary therapy.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Information provided by (Responsible Party): Jiuwu Bai, Shangha...